Ignite Creation Date:
2025-12-24 @ 3:30 PM
Ignite Modification Date:
2026-01-05 @ 6:05 PM
Study NCT ID:
NCT04956692
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-12-03
First Post:
2021-07-06
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)
Sponsor:
Merck Sharp & Dohme LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-08-05
Start Date Type:
ACTUAL
Primary Completion Date:
2023-04-04
Primary Completion Date Type:
ACTUAL
Completion Date:
2026-10-14
Completion Date Type:
ESTIMATED
First Submit Date:
2021-07-06
First Submit QC Date:
None
Study First Post Date:
2021-07-09
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2024-03-27
Results First Submit QC Date:
None
Results First Post Date:
2024-05-17
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-11-14
Last Update Post Date:
2024-12-03
Last Update Post Date Type:
ACTUAL